15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry dataR Baldassano, Harland S. Winter, Richard B. Colletti et al.|Journal of Crohn s and Colitis|2013Cited by 3
P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry dataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Journal of Crohn s and Colitis|2013Cited by 3
P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance studyFernando Magro, Séverine Vermeire, K Shan et al.|Journal of Crohn s and Colitis|2025Cited by 1
DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryDan Turner, Frank M. Ruemmele, Sibylle Koletzko et al.|Journal of Crohn s and Colitis|2018Cited by 0
Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryM Dubinsky, Meena Thayu, Jeffrey Hyams et al.|Journal of Crohns & Colitis|2016Cited by 0